Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03823768 · ClinicalTrials.gov registry record · Phase 4
Envarsus Neurotoxicity Burden in Liver Transplant Patients
A Phase 4 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03823768 is a Phase 4 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 30 participants.
The verdict
NCT03823768, a Phase 4 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will compare neurologic side effects associated with two immunosuppressant medications used in liver transplant patients. The standard therapy of twice daily immediate release Tacrolimus will be compared to Envarsus once daily. We hypothesize that Envarsus will show a lower rate of neurologic side effects than immediate release tacrolimus.
Interventions
- DRUG Envarsus
- DRUG Tacrolimus Immediate release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-01-31 |
| Est. Completion | 2024-01-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03823768
The ClinicalTrials.gov registry entry for NCT03823768 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Envarsus is the first listed.
NCT03823768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03823768 about?
NCT03823768 is a clinical study titled "Envarsus Neurotoxicity Burden in Liver Transplant Patients". This study will compare neurologic side effects associated with two immunosuppressant medications used in liver transplant patients. The standard therapy of twice daily immediate release Tacrolimus will be compared to Envarsus once daily. We hypothesize that Envarsus will show a lower rate of neurol...
What is the current status of trial NCT03823768?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2020-01-31. Estimated completion is 2024-01-30.
What interventions are being tested in trial NCT03823768?
The interventions under investigation include: Envarsus (DRUG), Tacrolimus Immediate release (DRUG).
Who is sponsoring clinical trial NCT03823768?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.